Selective serotonin receptor modulators and methods of making and using the same
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in developing safe and selective serotonin 2C receptor modulators that minimize activation of the 5-HT2A and 5-HT2B receptors, which are closely related to the 5-HT2C receptor, to avoid associated side effects such as hallucinations and cardiac valvulopathy, while targeting CNS disorders like obesity and mental disorders.
Innovation Solution
The development of conformationally constrained serotonin receptor agonists, represented by compounds of Formula I, which selectively target the 5-HT2C receptor with minimal impact on peripheral tissues, thereby reducing the activation of 5-HT2A and 5-HT2B receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serotonin receptor modulators are developed to treat CNS disorders, then therapeutic efficacy is improved, but activation of 5-HT2A and 5-HT2B receptors causes harmful side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (conformational constraints, cyclic structures, and defined substituent patterns) that create localized molecular characteristics. These structural modifications enable the compound to interact selectively with the 5-HT2C receptor binding site while avoiding activation of 5-HT2A and 5-HT2B receptors, thus achieving therapeutic efficacy with reduced side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including ring size (3- to 7-membered cyclic structures), substituent types (halo, alkyl, alkoxy, aryl, heteroaryl groups), and conformational constraints. These parameter modifications allow optimization of receptor selectivity, enabling the compound to maintain high affinity for 5-HT2C while minimizing activation of other serotonin receptor subtypes.
2Object-affected harmful factors
If compounds are designed to selectively activate 5-HT2C receptor, then safety is improved, but high conservation of molecular determinants in 5-HT2 subfamily makes selectivity difficult to achieve
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core cyclic structure (3- to 7-membered ring), specific substituent positions (R1 through R7), and conformational constraint elements. This segmentation allows independent optimization of each segment to achieve overall selectivity, where each segment contributes to specific interactions with the 5-HT2C receptor while avoiding cross-reactivity with other subtypes.
Solution Approach 2:
The patent employs asymmetry by introducing conformational constraints and asymmetric substituent patterns on the cyclic core structure. These asymmetric features create a non-superimposable molecular configuration that fits specifically into the 5-HT2C receptor binding pocket, exploiting subtle differences in the binding sites of 5-HT2A, 5-HT2B, and 5-HT2C receptors to achieve selective activation.
Data Source
AI summary
This disclosure relates to serotonin receptor modulators, including conformationally constrained serotonin receptor agonists, and methods of making and using the same are disclosed herein.